Senate Files

Bills

S. 775 118th Congress

Increasing Transparency in Generic Drug Applications Act

Latest action, Mar 14, 2023: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

How the Senate voted

The Senate hasn't taken a roll call on this bill in the Congresses covered.

3 cosponsors

Sponsored by Margaret Wood Hassan (Democrat). Cosponsors by party, House members included:

  • Democrats
  • Republicans
  • Independents
Cosponsors
1 D · 2 R
  • Democrat
  • Republican
  • Independent
3 senators cosponsoring

Referred to: Senate: Health, Education, Labor, and Pensions Committee

Who lobbied on it

Clients whose quarterly lobbying reports named it, each quarter.

16 clientsQ1 2023Q4 2024

The clients with the most reports naming it. A report's amount covers all of that client's lobbying in the quarter, not just this bill.

BIOTECHNOLOGY INNOVATION ORGANIZATION
8 reports
VIATRIS INC
8 reports
VIATRIS INC
WEST FRONT STRATEGIES LLC
8 reports
VIATRIS INC
HOLLAND & KNIGHT LLP
8 reports
ASSOCIATION FOR ACCESSIBLE MEDICINES
7 reports
PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION
7 reports
THE CAMPAIGN FOR SUSTAINABLE RX PRICING
MEHLMAN CONSULTING, INC.
7 reports
NATIONAL MULTIPLE SCLEROSIS SOCIETY
6 reports
ASSOCIATION OF ACCESSIBLE MEDICINES
MEHLMAN CONSULTING, INC.
5 reports
CAMPAIGN FOR SUSTAINABLE DRUG PRICING (CSRXP)
WHITMER & WORRALL, LLC
5 reports
GSK (FKA GLAXOSMITHKLINE INC.)
5 reports
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA
5 reports
CAMPAIGN FOR SUSTAINABLE DRUG PRICING
MCDERMOTT+ LLC
3 reports
VIATRIS INC
RAMPY NORTHRUP LLC
3 reports
ASSOCIATION OF ACCESSIBLE MEDICINES (FORMERLY KNOWN AS GPHA)
FIERCE GOVERNMENT RELATIONS
2 reports
All 25 of 26 clients
ClientLobbying firmReportsReports totalingFromToSenate
BIOTECHNOLOGY INNOVATION ORGANIZATION8$15.7MQ1 2023Q3 2024yes
VIATRIS INC8$5.4MQ1 2023Q3 2024yes
VIATRIS INCWEST FRONT STRATEGIES LLC8$0Q1 2023Q3 2024yes
VIATRIS INCHOLLAND & KNIGHT LLP8$0Q1 2023Q3 2024yes
ASSOCIATION FOR ACCESSIBLE MEDICINES7$4.0MQ4 2023Q3 2024yes
PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION7$28.0MQ1 2023Q3 2024yes
THE CAMPAIGN FOR SUSTAINABLE RX PRICINGMEHLMAN CONSULTING, INC.7$380KQ4 2023Q3 2024yes
NATIONAL MULTIPLE SCLEROSIS SOCIETY6$393KQ4 2023Q3 2024yes
ASSOCIATION OF ACCESSIBLE MEDICINESMEHLMAN CONSULTING, INC.5$280KQ4 2023Q3 2024yes
CAMPAIGN FOR SUSTAINABLE DRUG PRICING (CSRXP)WHITMER & WORRALL, LLC5$120KQ4 2023Q3 2024yes
GSK (FKA GLAXOSMITHKLINE INC.)5$5.8MQ4 2023Q2 2024yes
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA5$35.7MQ4 2023Q2 2024yes
CAMPAIGN FOR SUSTAINABLE DRUG PRICINGMCDERMOTT+ LLC3$90KQ4 2023Q3 2023yes
VIATRIS INCRAMPY NORTHRUP LLC3$0Q1 2023Q3 2023yes
ASSOCIATION OF ACCESSIBLE MEDICINES (FORMERLY KNOWN AS GPHA)FIERCE GOVERNMENT RELATIONS2$100KQ1 2023Q2 2023yes
BCBSM INC2$62KQ4 2024Q3 2024yes
BLUE CROSS AND BLUE SHIELD ASSOCIATION2$3.7MQ4 2024Q3 2024yes
BLUE CROSS AND BLUE SHIELD OF FLORIDA INC2$360KQ4 2024Q3 2024yes
BLUE CROSS AND BLUE SHIELD OF KANSAS INC2$15KQ4 2024Q3 2024yes
GUIDEWELL MUTUAL HOLDING CORPORATION2$30KQ4 2024Q3 2024yes
PHARMACEUTICAL RESEARCH & MANUFACTURERS OF AMERICA INCCOVINGTON & BURLING LLP2$0Q2 2023Q2 2024yes
PUBLIC CITIZEN2$141KQ4 2023Q2 2023yes
BLUE CROSS BLUE SHIELD OF MICHIGAN1$269KQ4 2024Q4 2024yes
CENTER FOR HEALTH AND DEMOCRACYPORT SIDE STRATEGIES, LLC1$20KQ4 2023Q4 2023yes
NEW VENTURE FUNDPORT SIDE STRATEGIES, LLC1$0Q4 2023Q4 2023yes